Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783926 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
A Phase 1 study, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 422
- Enrollment target
NCT00783926: Completed Phase 1 study, sponsored by Alachua Government Services.
NCT00783926 is a Phase 1 study that has completed, run by Alachua Government Services. The registered enrollment target is 422 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (603% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783926, a Phase 1 study, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 422 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a healthy young adult population. Subjects will receive 2 vaccinations (21 days apart) at the dose to which they were assigned. Blood will be drawn from all subjects for serum antibody determination on Days 0, 21, 42 and 180. Body temperature will be measured daily for 6 days following vaccination. Injection site reactions and systemic reactions will be monitored throughout the entire 180 days of the study. Safety data obtained at 7 days after the first vaccination for all dose levels in Cohort 1 will be reviewed by a Data Monitoring Committee and a recommendation will be obtained whether to proceed to the second vaccination of Cohort 1 and to the first vaccination of Cohort 2.
Interventions
- BIOLOGICAL H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00783926 record still lists
NCT00783926 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (603% higher).
The record links to 0 conditions, and to 1 intervention - of which H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen) is the first listed.
NCT00783926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783926 about?
NCT00783926 is a clinical study titled "Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)". The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a healthy young adult population. Subjects will receive 2 vaccinations (21 da...
What is the current status of trial NCT00783926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 422 participants. The study started on 2008-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00783926?
The interventions under investigation include: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783926?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00783926's enrollment target sits among peer trials
422 65th of 2000 higher than 1,936 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia